1 National Health Commission. 2018 Statistical Bulletin of China's Health Development. 2020. http://www.gov.cn/guoqing/2020-04/29/content_5507528.htm. Accessed March 20, 2021.
2 The General Office of the State Council. Notice of the General Office of the State Council on Issuing the Pilot Program for the Centralized Procurement and Use of Drugs Organized by the State. 2019. http://www.gov.cn/zhengce/content/2019-01/17/content_5358604.htm. Accessed March 18, 2021.
3 Mao Z, Yang Y, Chen L. Reform of Drug Supply and Guarantee System in China: Policy Measures and Effects. In: Wang C, Liang W, editors. Development Report on Health Reform in China (2020). Beijing: Social Sciences Academic Press; 2020. p. 96-123.
4 Li Y, Yang L, Wang L, Zhang M, Huang Z, Deng Q et al. Burden of hypertension in China: A nationally representative survey of 174 621 adults. INT J CARDIOL. 2016;227:516-23. doi: 10.1016/j.ijcard.2016.10.110.
5 Chinese Pharmaceutical Association. Hospital Drug Monitoring Report 2019. 2020. https://www.cpa.org.cn//?do=info&cid=75104. Accessed March 10, 2021.
6 Zhang W, Xu W, Yang X. Drug burden of antihypertensive drugs in 87 county level hospitals in China. Chongqing Medicine. 2020;49(19):3303-5. doi: 10.3969/j.issn.1671-8348.2020.19.035.
7 Xu Y, He J, Chen M, Song J, Jin C. International Experience of Centralized Drug Procurement and Enlightenment to China's National Level Volume-based Drug Procurement. Chinese Health Economics. 2021;40(04):93-6
8 National Health Development Research Center of the National Health Commission. 2018 China Total Health Expenditure Research Report. 2018.
9 Joint Procurement Office. Announcement of the results of the planned selection of centralized drug procurement in 4+7 cities. 2018. http://www.smpaa.cn/gjsdcg/2018/12/07/8531.shtml. Accessed March 22, 2021.
10 Ye S, Kang Q, Gao J, Chen Q, Hu S, Cai H et al. Study Of Drug Price Index in Evaluating Implementation Effect of "4+7" Drug Centralized Procurement Policy in Fujian. China Health Insurance. 2020(08):35-9. doi: 10.19546/j.issn.1674-3830.2020.8.008.
11 Shenzhen Healthcare Security Bureau. Pilot Analysis on Drug Centralized Procurement and Use Organized by the State in Shenzhen. China Health Insurance. 2019(08):32-7. doi: 10.19546/j.issn.1674-3830.2019.8.008.
12 Huang D, Li Z, Zhao Q. Practice and Consideration of Drug Centralized Procurement and Use in Chengdu. China Health Insurance. 2019(08):20-3. doi: 10.19546/j.issn.1674-3830.2019.8.005.
13 Mu A. Preliminary Analysis on the Pilot Project of Drug Centralized Procurement and Use in Chongqing. China Health Insurance. 2019(08):24-7. doi: 10.19546/j.issn.1674-3830.2019.8.006.
14 Meng L. Analysis on the Pilot Operation of Drug Centralized Procurement and Use in Shenyang. China Health Insurance. 2019(08):28-31. doi: 10.19546/j.issn.1674-3830.2019.8.007.
15 Chen H, Liu Y, Yu X, Zhang D, Zhou H, Feng W et al. Data Analysis on Pilot Reform of Drug Centralized Procurement and Use——Taking Beijing Chaoyang Hospital as an Example. China Health Insurance. 2019(08):51-3. doi: 10.19546/j.issn.1674-3830.2019.8.012.
16 Wang N, Yang Y, Xu L, Mao Z, Cui D. Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series
analysis. Preprints. 2021(2021040157). doi: 10.20944/preprints202104.0157.v1.
17 Wang H, Li X, Chen J. Impact of "4+7" City Drug Centralized Procurement Program on the utilization of original and generic cardiovascular drugs in a tertiary hospital. Journal of Pharmaceutical Practice. 2020;38(04):373-8. doi: 10.12206/j.issn.1006-0111.202001054.
18 Yang Q, Gu H. Investigation of the implementation status of national centralized drug procurement in community health service centers of Shanghai. Shanghai Medical & Pharmaceutical Journal. 2020;41(04):11-4
19 He J, Tang M, Cong L, Xu Y, Song J, Chen M et al. The impact of National Centralized Drug Procurement on the clinical management and drug use. Chinese Health Resources. 2021:1-3. doi: 10.13688/j.cnki.chr.2021.200802.
20 General Office of the State Council of the PRC. Pilot Program for National Centralized Drug Procurement and Use. 2019. http://www.gov.cn/zhengce/content/2019-01/17/content_5358604.htm. Accessed March 20, 2021.
21 Wang Y, Wu Z. Keypoint Analysis of Monitoring Plan for Centralized Drug Purchase and Use Project Pilot Launched Organized by State. China Pharmacy. 2019;30(17):2317-22. doi: 10.6039/j.issn.1001-0408.2019.17.03.
22 Deng J, Tian H, Guo Y, Ma T, Sun Y, Zhang S et al. A retrospective and prospective assessment of the zero-markup drug reform in China from the perspective of policy diffusion. Int J Health Plann Manage. 2018;33(4):e918-29. doi: 10.1002/hpm.2562.
23 General Office of the State Council. Guiding Opinions on Improving the Centralized Drug Procurement in Public Hospitals (Guobanfa  No. 7). 2015. http://www.gov.cn/zhengce/content/2015-02/28/content_9502.htm. Accessed March 20, 2021.
24 Joint Procurement Office. 4+7 City Drug Centralized Procurement Documents (No. GY-YD2018-1). 2018. http://www.smpaa.cn/gjsdcg/2018/11/15/8511.shtml. Accessed March 20, 2021.
25 WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2021. 2020. https://www.whocc.no/atc_ddd_index/. Accessed March 20, 2021.
26 WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2021, Norway. 2021. http://www.whocc.no. Accessed March 20, 2021.
27 Lagarde M. How to do (or not to do) ... Assessing the impact of a policy change with routine longitudinal data. HEALTH POLICY PLANN. 2011;27(1):76-83. doi: 10.1093/heapol/czr004.
28 Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J CLIN PHARM THER. 2002;27(4):299-309. doi: 10.1046/j.1365-2710.2002.00430.x.
29 Zhang F, Wagner AK, Soumerai SB, Ross-Degnan D. Methods for estimating confidence intervals in interrupted time series analyses of health interventions. J CLIN EPIDEMIOL. 2009;62(2):143-8. doi: 10.1016/j.jclinepi.2008.08.007.
30 Baum CF, Schaffer ME. ACTEST: Stata module to perform Cumby-Huizinga general test for autocorrelation in time series. 2013. https://ideas.repec.org/c/boc/bocode/s457668.html.
31 Linden A. Conducting interrupted time-series analysis for single- and multiple-group comparisons. The Stata Journal. 2015;15(2):480-500
32 Durbin J, Watson GS. Testing for serial correlation in least squares regression. I. BIOMETRIKA. 1950;37(3-4):409-28
33 National Healthcare Security Administration of the People's Republic of China. Answer to Reporters' Request about the Second Round of National Centralized Drug Procurement and Use. 2020. http://www.nhsa.gov.cn/art/2020/1/17/art_38_2264.html.
34 Hursh SR. Behavioral economics of drug self-administration: an introduction. DRUG ALCOHOL DEPEN. 1993;33(2):165-72. doi: https://doi.org/10.1016/0376-8716(93)90058-X.
35 Hursh S, Bauman R. The behavioral analysis of demand. In: Green L, Kagel J, editors. Advances in behavioral economics: Ablex, Norwood, NJ; 1987. p. 117-65.
36 Yang Y, Chen L, Ke X, Mao Z, Zheng B. The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018-2019: an interrupted time-series analysis. BMC Health Services Research (Preprints). 2021. doi: 10.21203/rs.3.rs-143454/v1.
37 Yu C. The practical effects and system concerns of "4+7" drug procurement. Journal of Southwest Minzu University (Humanities and Social Science). 2020;41(04):34-9
38 Yang Q, Zang Y, Zhuang H, Guo W. Effects of "4+7" procurement with target quantity on the using of antidepressants in a hospital. Chinese Journal of Hospital Pharmacy. 2020;40(13):1479-83. doi: 10.13286/j.1001-5213.2020.13.16.
39 Sheng L, Li X, Hu X. Application of Nucleoside Anti-hepatitis B Drugs Based on “4+7” Quantified Purchasing. China Journal of Pharmaceutical Economics. 2019;14(07):36-9. doi: 10.12010/j.issn.1673-5846.2019.07.007.
40 National Academies of Sciences EAM, Division HAM, Services BOHC, Therapies COEP. Making Medicines Affordable: A National Imperative. Washington (DC): National Academies Press (US); 2017.
41 Li H, Zhu J, CHhen Y. Usage of Original and Generic Antihypertensive Drugs in a Special Outpatient Department of a Hospital. China Pharmaceuticals. 2019;28(10):90-3. doi: 10.3969/j.issn.1006-4931.2019.10.030.
42 Gheorghe A, Griffiths U, Murphy A, Legido-Quigley H, Lamptey P, Perel P. The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review. BMC PUBLIC HEALTH. 2018;18(1):975. doi: 10.1186/s12889-018-5806-x.
43 Wang X, Zhang M, Zhao S, Lv M, Li Q, He L et al. Investigation on Household Medication-Taking Behavior and Affordability Among Patients Under Chronic Condition: A Survey Study in Gansu Province, China. FRONT PHARMACOL. 2020;11:1280. doi: 10.3389/fphar.2020.01280.